Planning and core analyses for periodic aggregate safety data reviews

Clinical Trials

Volumn 8, Issue 2, 2011, Pages 175-182

  Xia, H Amy ^a   Crowe, Brenda J ^b   Schriver, Robert C ^c   Oster, Manfred ^d   Hall, David B ^e  

^a AMGEN INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c GLAXOSMITHKLINE   (United States)

^d SANOFI   (France)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTHOR; CLINICAL TRIAL (TOPIC); INSTITUTIONAL REVIEW; META ANALYSIS (TOPIC); PLANNING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SAFETY;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA COLLECTION; DRUG TOXICITY; HUMANS; SAFETY MANAGEMENT;

EID: 79959216544     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774510395635     Document Type: Review

References (13)

1. United States Food and Drug Administration. Guidance for industry and investigators. Safety reporting requirements for INDs and BA/BE studies. Draft guidance, 2010. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM227351.pdf (accessed 27 October 2010).
2. Crowe BJ, Xia HA, Berlin JA, et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the Safety Planning, Evaluation and Reporting Team (SPERT). Clin Trials 2009; 6: 430-40.
3. Council for International Organizations of Medical Sciences (CIOMS) Working Group VI. Management of safety information from clinical trials, Geneva, 2005.
4. Chuang-Stein C, Beltangady M. Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies. Pharma Stat 2010. Published online. DOI: 10.1002/pst.397.
5. Berry SM, Berry DA. Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model. Biometrics 2004; 60: 418-26. (Pubitemid 38780201)
6. Xia HA, Ma H, Carlin BP. Bayesian hierarchical modeling for detecting safety signals in clinical trials. J Biopharm Stat. In press.
7. Southworth H, O'Connell M. Data mining and statistically guided clinical review of adverse event data in clinical trials. J Biopharm Stat 2009; 19: 803-17.
8. Amit O, Heiberger RM, Lane PW. Graphical approaches to the analysis of safety data from clinical trials. Pharma Stat 2008; 7: 20-35. (Pubitemid 351385323)
9. Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. BMJ 2001; 322: 1479-80. (Pubitemid 32575420)
10. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley, New York, 1980.
11. United States Food and Drug and Administration. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM174090.pdf (accessed 27 October 2010).
12. Guo T, Gelperin K, Senior J. (2008). A tool to help you decide: detect potentially serious liver injury. Available at: http://www.fda.gov/downloads/ Drugs/ScienceResearch/ResearchAreas/ucm076777.pdf (accessed 27 October 2010).
13. Watkins PB. When should an investigational drug be stopped during a trial? Available at: http://www.fda.gov/downloads/Drugs/ScienceResearch/ ResearchAreas/ucm077494.pdf (accessed 27 October 2010).